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Abstract
Human cytomegalovirus (HCMV) infection is the major viral complication in solid organ transplant
recipients. Seronegative recipents (R-) of organs from seropositive donors (D+) appear to be at
higher risk of developing symptomatic HCMV infection. To what extent systemic life-threatening
complications can be risked for non-life-saving transplant procedures? A case report describing
successful treatment of repeated episodes of active HCMV infection in a D+R- hand recipient in the
absence of HCMV-specific T-cell immunity is presented. In the attempt to save both the patient and
the transplanted hand, a preemptive treatment strategy was adopted with the aim to boost the
constitution of the virus-specific T-cell immune response and simultaneously avoid onset of disease.
Careful monitoring of HCMV load in blood and HCMV-specific T-cell immunity guided
administration of repeated courses of antiviral treatment and avoided emergence of HCMV-related
symptoms. Following establishment of HCMV-specific CD4+ and CD8+ T-cell response, preemptive
treatment was no longer required due to sustained HCMV disappearance from blood. The patient
is now well, and his hand too. In conclusion, evaluation of virus-specific T-cell immunity is of crucial
importance in D+R- transplant recipients and careful monitoring of HCMV-specific T cell mediated
response should always parallel monitoring of HCMV load in transplant recipients.
Introduction
Since the first successful hand transplantation in Lyon in
1998, 38 hands (18 unilateral and 10 bilateral) and two
digits have been transplanted in 30 individuals in differ-
ent countries [1]. Notwhistanding the value of such expe-
rience pioneering composite tissue transplantation and
allowing to explore other transplant frontiers such as face
and limb transplantation, clinicians continue to debate
about the risk acceptability of such procedures [2].
Indeed, the functional and psychologic benefits of hand
transplantation may be counterbalanced by the risk of
potentially severe systemic complications due to immune
suppression. In some instance, the clinicians may face the
difficult decision of amputating a successfully trans-
planted hand in order to interrupt the immunosuppres-
sive treatment in the attempt to solve a life threatening
opportunistic infection. One of the most challenging viral
infections in transplant recipients is human cytomegalo-
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virus (HCMV) infection, namely in HCMV-seronegative
recipients (R-) of grafts from HCMV-seropositive donors
(D+) [3].
The case of a D+R- hand transplant recipient with recurrent
episodes of disseminated HCMV infection associated with
impaired HCMV-specific CD4+ and CD8+ T cell response
is described.
Case presentation
In October 2002, a 33 year-old HCMV-seronegative cau-
casic male who had lost his dominant right hand at the
wrist level in a car crash 10 years before was submitted to
hand transplantation from a HCMV-seropositve donor.
Immune suppressive treatment included tacrolimus, myc-
ophenolate mofetil and steroids. Kinetics of HCMV infec-
tion was monitored by quantitative determination of
antigenemia and DNAemia [4]. Antigenemia consists of
quantitative determination of HCMV pp65-positive/2 ×
105 leukocytes examined in a cytospin preparation [4].
DNAemia consists of quantitation of HCMV genome by
PCR in blood and was expressed as HCMV DNA copy
number/10 uL whole blood [4].
HCMV antiviral prophylaxis with i.v. ganciclovir (5 mg/
Kg/die) was administered for 30 days starting fom day 2
after transplantation. Afterwards, a preemptive antiviral
treatment approach was adopted. In detail, antiviral drug
were administered in the absence of overt clinical symp-
toms when in the presence of active HCMV infection as
documented by positive antigenemia values [4].
On day 42, a severe acute rejection episode required
antithymocyte globulin administration to be controlled.
Soon thereafter, HCMV antigenemia level started increas-
ing and by day 85 reached 1200 pp65-positive/2 × 105
leukocytes examined, in the absence of overt HCMV dis-
ease. Administration of foscarnet, cidofovir and anti-CMV
hyperimmune globulin was successful in controlling
HCMV infection. Preemptive treatment with valgancyclo-
vir was then scheduled to initiate at the first confirmed
positive antigenemia result in order to prevent HCMV dis-
ease. During the following 3 years, antigenemia and
DNAemia were found to be repeatedly positive (Figure
1A), thus prompting administration of several courses of
antiviral treatment. The prolonged and repeated episodes
of HCMV disseminated infection in the absence of other
opportunistic infections suggested a potential selective
impairment of HCMV-specific T-cell mediated immune
response. The hypothesis was verified by investigating
HCMV-specific CD4+  and CD8+  T-cell responses by a
newly developed assay [5]. In detail, after in vitro differen-
tiation from peripheral blood mononuclear cells (PBMC)
separated by Lymphoprep™ (Axis-Shield PoC AS, Oslo,
Norway) density gradient centrifugation, immature den-
dritic cells (DC) were infected for 24 h with an endotheli-
otropic strain of HCMV. As a control, DC were mock-
infected with the clarified medium of uninfected endothe-
lial cell cultures. HCMV-infected or mock-infected DC
were cocultured overnight with thawed autologous PBMC
or the non-adhering fraction of PBMC in the presence of
brefeldin A (Sigma, St. Louis, MO). Then, PBMC were
tested for intracellular interferon-γ(IFNγ) production by a
cytokine flow cytometry assay. The frequency of CD4+ and
CD8bright T cells producing IFNγ in response to HCMV
stimuli were calculated by subtracting the value of the
sample incubated with mock-infected culture medium or
control antigen (consistently < 0.05%) from the test
value. Absolute CD3+CD4+ and CD3+CD8+ T cell counts
were determined on heparin-treated peripheral blood
samples by a direct immunofluorescent flow cytometry
method (Epics-XL, Beckman Coulter Inc.). To determine
the total number of HCMV-specific CD4+ and CD8+ T
cells, the percentages of HCMV-specific T cells positive for
IFNγ were multiplied by the relevant absolute CD4+ and
CD8+ T cell count. A cut-off value of 0.4 IFNγ- positive
CD4+ and CD8+ T cells/μl indicated presence of HCMV-
specific CD4+ and CD8+ T-cell immunity [6].
Due to unavailability of other D+R- composite tissue recip-
ients as controls, results of T-cell immunity were com-
pared with those of some D+R- solid organ transplant
recipients (SOTR) with primary HCMV infection.
Immune suppressive regimen included cyclosporine-A,
mycophenolate mofetil and steroids in 1 patient, tac-
rolimus, mycophenolate mofetil and steroids in 2 other
patients, and cyclosporina-A, azathioprine, and steroids
in the remaining 2 patients.
The hand transplanted patient showed absolute CD4+ T
cell counts consistently < 100 for over 3 years after trans-
plantation. HCMV-specific CD8+  T cell response was
below the cut-off value till 21 months after transplanta-
tion, and HCMV-specific CD4+  T cell response was
impaired till 35 months after transplantation (Figure 1B).
Coincidental with the lack of HCMV-specific CD4+ and
CD8+ T cell response was the consistent positivity of viral
markers in blood prompting antiviral treatment, while
recovery of HCMV-specific CD4+  and CD8+  T-cell
reponses was associated with spontaneous resolution of
viral infection (Figure 1A and 1B). To date, antigenemia
and DNAemia remain negative in the absence of antiviral
treatment. As shown in Figure 1C, control D+R- SOTR
patients developing an effective T-cell response showed
HCMV-specific CD8+ and CD4+ T-cell levels above the cut-
off value by month 3 and 4 after transplantation, respec-
tively. In parallel with the progressive increase of the
HCMV-specific T-cell response, the progressive decrease of
peak HCMV DNA levels in blood was observed. As a con-
sequence, the number of HCMV infection episodesCases Journal 2008, 1:155 http://www.casesjournal.com/content/1/1/155
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(A) Monthly peak HCMV antigenemia and DNAemia levels in a D+R- hand transplant recipient Figure 1
(A) Monthly peak HCMV antigenemia and DNAemia levels in a D+R- hand transplant recipient. (B) HCMV-spe-
cific CD4+ and CD8+ T cell counts in the same patient. (C) Monthly HCMV peak DNAemia levels and HCMV-specific CD4+ 
and CD8+ median T-cell counts in 6 D+R- solid organ transplant recipients undergoing primary HCMV infection and mounting 
an efficient T-cell immune response. The cut-off value for HCMV-specific T-cell reponse was fixed at 0.4 INFγ producing CD4+ 
and CD8+ T-cells/uL [10].
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requiring preemptive treatment in control SOTR progres-
sively decreased.
D+R- serostatus represents a major risk factor for severe
HCMV infections in SOTR [3]. In addition, only D+R-
patients have repeatedly been reported to be at risk for
development of drug-resistant HCMV infections among
SOTR [4,7]. However, in the great majority of D+R- SOTR,
HCMV primary infection can be successfully controlled by
antiviral treatment. In addition, immunosuppressive regi-
mens do not avoid in the majority of SOTR development
of HCMV-specific T-cell response of the same amplitude
as in immunocompetent individuals [8]. On the other
hand, a few reports associated the emergence of drug-
resistant HCMV strains in SOTR following prolonged anti-
viral drug administration with the sustained impairment
of HCMV-specific T-cell response [4,9,10]. Thus, the lack
of HCMV-specific immunity in individual SOTR appears
to play a major role in the pathogenesis of severe HCMV
infections in transplanted patients.
Hand transplantation is not a life-saving procedure and it
could be argued that it should be avoided in seronegative
recipients since development of HCMV-specific immune
response might be impaired in individual patients under-
going primary HCMV infection. In these cases, the antivi-
ral treatment alone would be expected to be unable to
control the repeated episodes of active HCMV infection
with the potential risk of major complications such as
development of overt disease or emergence of drug-resist-
ant HCMV strains. For 3 years our patient was lacking
HCMV-specific T cell immunity. This delay in mounting
an efficient anti-HCMV cellular response is likely to be the
major responsible for the recurrent episodes of dissemi-
nated HCMV infection. However, major complications
were avoided in our patient by adoption of a tight viro-
logic monitoring and repeated preemptive treatment
courses. As a conclusion, a careful monitoring of HCMV-
specific T-cell mediated immune response should parallel
monitoring of HCMV load also in composite tissue trans-
plant recipient.
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